<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="32c41cf3-97c0-018d-e063-6394a90ad851"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ATROPINE SULFATE OPHTHALMIC SOLUTION, USP 1% safely and effectively. See full prescribing information for ATROPINE SULFATE OPHTHALMIC SOLUTION, USP 1%.
 <br/>
      <br/>
ATROPINE SULFATE OPHTHALMIC SOLUTION, USP 1%, for topical ophthalmic use
 <br/>
Initial U.S. Approval: 1960
</title>
   <effectiveTime value="20250414"/>
   <setId root="e294ce2b-6bb5-4f84-8a6d-ce2402ed926d"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="118287629"/>
            <name>Bausch &amp; Lomb Americas Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079176615"/>
                        <name>Unither Manufacturing LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82260-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="32c4214f-1824-5ff4-e063-6294a90a234b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250414"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82260-001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Atropine Sulfate</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Atropine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="03J5ZE7KA5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATROPINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7C0697DR9I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATROPINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="82260-001-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230421"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213581" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230421"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_932d11bf-28f8-4bf1-84d5-ac7f3d44f971">
               <id root="32c41cf3-97c1-018d-e063-6394a90ad851"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Atropine Sulfate Ophthalmic Solution, USP 1% is indicated for:</paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Atropine is an anti-muscarinic agent indicated for:</paragraph>
                        <list listType="unordered">
                           <item>Mydriasis (
  
     <linkHtml href="#ID_f949de0d-430d-41f6-b2a0-383376a10688">1.1</linkHtml>)
 
    </item>
                           <item>Cycloplegia (
  
     <linkHtml href="#ID_b2752420-9959-4b55-821a-bb3d37e4aab9">1.2</linkHtml>)
 
    </item>
                           <item>Penalization of the healthy eye in the treatment of amblyopia (
  
     <linkHtml href="#ID_0b5932e4-8cf7-4dba-aab0-5f2888ff6df7">1.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f949de0d-430d-41f6-b2a0-383376a10688">
                     <id root="32c41cf3-97c2-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Mydriasis</title>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b2752420-9959-4b55-821a-bb3d37e4aab9">
                     <id root="32c41cf3-97c3-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Cycloplegia</title>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0b5932e4-8cf7-4dba-aab0-5f2888ff6df7">
                     <id root="32c41cf3-97c4-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Penalization of the Healthy Eye in the Treatment of Amblyopia</title>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_26236c0c-38ba-4aad-a7a5-f169321ecfd2">
               <id root="32c41cf3-97c5-018d-e063-6394a90ad851"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva in one or both eyes as indicated, forty minutes prior to the intended maximal dilation time.</paragraph>
                  <paragraph>In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed.</paragraph>
                  <paragraph>Discard the single-dose vial immediately after use in one or both eyes.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time (2.1).</item>
                           <item>In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed (2.2).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f928242c-43ce-483c-8949-67e09ea9c203">
               <id root="32c41cf3-97c6-018d-e063-6394a90ad851"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Atropine Sulfate Ophthalmic Solution, USP 1%: each mL contains 10 mg of atropine sulfate.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution: 1% atropine sulfate (10 mg/mL) (
 
    <linkHtml href="#_RefID_f928242c-43ce-483c-8949-67e09ea9c">3</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1bac374d-d6b4-40c1-964f-0e9ae5015da7">
               <id root="32c41cf3-97c7-018d-e063-6394a90ad851"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Atropine Sulfate Ophthalmic Solution, USP 1% should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity or allergic reaction to any ingredient in the formulation (
 
    <linkHtml href="#_RefID_1bac374d-d6b4-40c1-964f-0e9ae5015">4</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_d2c85913-802a-4a03-87a4-56fe20b1c9fc">
               <id root="32c41cf3-97c8-018d-e063-6394a90ad851"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks (
  
     <linkHtml href="#ID_2baa87a0-ef32-4333-9083-e6dafc453fc9">5.1</linkHtml>).
 
    </item>
                           <item>Risk of blood pressure increase from systemic absorption (
  
     <linkHtml href="#ID_295b335f-c024-4edf-988c-c62480960fb3">5.2</linkHtml>).
 
    </item>
                           <item>To avoid the potential for eye injury or contamination, care should be taken to avoid touching the single-dose vial to the eye or to any other surface (
  
     <linkHtml href="#ID_50e92707-8d80-4edf-b260-a230cc1f1386">5.3</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2baa87a0-ef32-4333-9083-e6dafc453fc9">
                     <id root="32c41cf3-97c9-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Photophobia and Blurred Vision</title>
                     <text>
                        <paragraph>Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_295b335f-c024-4edf-988c-c62480960fb3">
                     <id root="32c41cf3-97ca-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Elevation of Blood Pressure</title>
                     <text>
                        <paragraph>Elevation in blood pressure from systemic absorption has been reported following conjunctival instillation of recommended doses of Atropine Sulfate Ophthalmic Solution, USP 1%.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_50e92707-8d80-4edf-b260-a230cc1f1386">
                     <id root="32c41cf3-97cb-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Potential for Eye Injury or Contamination</title>
                     <text>
                        <paragraph>To avoid the potential for eye injury or contamination, care should be taken to avoid touching the single-dose vial to the eye or to any other surface.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bc5b91ba-d1a8-4aef-815f-e7933d0cee62">
               <id root="32c41cf3-97cc-018d-e063-6394a90ad851"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Photophobia and Blurred Vision
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_2baa87a0-ef32-4333-9083-e6dafc453fc9">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Elevation in Blood Pressure
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_295b335f-c024-4edf-988c-c62480960fb3">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been identified following use of atropine sulfate ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions that have been reported are eye pain and stinging on administration, blurred vision, photophobia, superficial keratitis, decreased lacrimation, drowsiness, increased heart rate and blood pressure (
 
    <linkHtml href="#_RefID_bc5b91ba-d1a8-4aef-815f-e7933d0ce">6</linkHtml>).

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or
  
     <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_cca73a7a-d1e4-418c-9623-d71ca9c90132">
                     <id root="32c41cf3-97cd-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Ocular Adverse Reactions</title>
                     <text>
                        <paragraph>Eye pain and stinging occurs upon instillation of atropine sulfate ophthalmic solution. Other commonly occurring adverse reactions include blurred vision, photophobia, superficial keratitis and decreased lacrimation. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and eyelid edema may also occur less commonly.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0cc766f2-2e1c-4767-b3ee-5aec92ef8ac7">
                     <id root="32c41cf3-97ce-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Systemic Adverse Reactions</title>
                     <text>
                        <paragraph>Systemic effects of atropine are related to its anti-muscarinic activity. Systemic adverse events reported include dryness of skin, mouth, and throat from decreased secretions from mucous membranes; drowsiness, restlessness, irritability or delirium from stimulation of the central nervous system; tachycardia; flushed skin of the face and neck.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bdc222c0-ec6a-4bd6-8e33-8d687e0a9193">
               <id root="32c41cf3-97cf-018d-e063-6394a90ad851"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20220303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis (
 
    <linkHtml href="#_RefID_bdc222c0-ec6a-4bd6-8e33-8d687e0a9">7</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_67d4971d-ca93-4162-b48f-f404e6ef1c02">
                     <id root="32c41cf3-97d0-018d-e063-6394a90ad851"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Monoamine Oxidase Inhibitors (MAOI)</title>
                     <text>
                        <paragraph>The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_905ec84d-8794-48f1-8fa4-c351af49e27b">
               <id root="32c41cf3-97d1-018d-e063-6394a90ad851"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20220303"/>
               <component>
                  <section ID="ID_fdee0fee-7a23-4b5e-b78e-0778ecd5d912">
                     <id root="32c41cf3-97d2-018d-e063-6394a90ad851"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of Atropine Sulfate Ophthalmic Solution, USP 1% administration in pregnant women to inform a drug-associated risk. Adequate animal development and reproduction studies have not been conducted with atropine sulfate. In humans, 1% atropine sulfate is systemically bioavailable following topical ocular administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID_b84a9df1-e320-4898-ae9e-0399382698ff">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>. Atropine Sulfate Ophthalmic Solution, USP 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

 </paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8226a183-4f1d-4813-af9c-c82fb6720933">
                     <id root="32c41cf3-97d3-018d-e063-6394a90ad851"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information to inform risk regarding the presence of atropine in human milk following ocular administrations of Atropine Sulfate Ophthalmic Solution, USP 1% to the mother. The effects on breastfed infants and the effects on milk production are also unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Atropine Sulfate Ophthalmic Solution, USP 1% and any potential adverse effects on the breastfed child from Atropine Sulfate Ophthalmic Solution, USP 1%.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0a0c593c-5610-456d-a6e1-522e6ccf44a4">
                     <id root="32c41cf3-97d4-018d-e063-6394a90ad851"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Due to the potential for systemic absorption, the use of Atropine Sulfate Ophthalmic Solution, USP 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day. Safety and efficacy in children above the age of 3 months has been established in adequate and well controlled trials.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0e5ecaa3-8611-4c95-81f1-2a4655d14e8e">
                     <id root="32c41cf3-97d5-018d-e063-6394a90ad851"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b0f107af-f791-40fc-875d-ef4d533b0fcf">
               <id root="32c41cf3-97d6-018d-e063-6394a90ad851"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of accidental ingestion or toxic overdosage with Atropine Sulfate Ophthalmic Solution, USP 1%, supportive care may include a short acting barbiturate or diazepam as needed to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended.</paragraph>
                  <paragraph>Physostigmine, given by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required.</paragraph>
                  <paragraph>Artificial respiration with oxygen may be necessary. Cooling measures may be needed to help to reduce fever, especially in pediatric populations.</paragraph>
                  <paragraph>The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
            </section>
         </component>
         <component>
            <section ID="ID_6985d103-b5a8-476e-b3dd-bd1efe7ef4ca">
               <id root="32c41cf3-97d7-018d-e063-6394a90ad851"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Atropine Sulfate Ophthalmic Solution, USP 1% is an aseptically prepared, sterile solution for topical ophthalmic use. The product does not contain an antimicrobial preservative. The active ingredient is represented by the chemical structure:</paragraph>
                  <renderMultiMedia ID="id-907225198" referencedObject="B2CF3B86-6E3D-45B3-A251-AA0943D3F898"/>
                  <paragraph>
                     <content styleCode="bold">Chemical Name:</content>           Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1.]oct-3-yl ester, endo –(±)-, sulfate (2:1) (salt), monohydrate.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Molecular Formula:</content>     (C
 
  <sub>17</sub>H
 
  <sub>23</sub>NO
 
  <sub>3</sub>)
 
  <sub>2</sub>• H
 
  <sub>2</sub>SO
 
  <sub>4</sub>• H
 
  <sub>2</sub>O

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Molecular Weight:</content>        694.84 g/mol

 </paragraph>
                  <paragraph>Each mL of Atropine Sulfate Ophthalmic Solution, USP 1% contains:
 
  <content styleCode="bold">Active:</content>atropine sulfate 10 mg equivalent to 8.3 mg of atropine.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives:</content>boric acid, hydroxypropyl methylcellulose, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection USP.

 </paragraph>
               </text>
               <effectiveTime value="20220303"/>
               <component>
                  <observationMedia ID="B2CF3B86-6E3D-45B3-A251-AA0943D3F898">
                     <text>chemstructure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemstructure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6460f9a3-9713-46bf-b875-b440557a769e">
               <id root="32c41cf3-97d8-018d-e063-6394a90ad851"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220303"/>
               <component>
                  <section ID="ID_966e5793-ea17-43bf-ae33-33950a1b2715">
                     <id root="32c41cf3-97d9-018d-e063-6394a90ad851"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Atropine is a reversible antagonist of muscarine-like actions of acetylcholine and is therefore classified as an anti-muscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.</paragraph>
                        <paragraph>The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c93be3ae-0c55-483f-929e-113ab07c8db9">
                     <id root="32c41cf3-97da-018d-e063-6394a90ad851"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The onset of action after administration of Atropine Sulfate Ophthalmic Solution, USP 1% generally occurs within minutes with maximal effect seen in hours and the effect can last multiple days
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID_ac7c1d64-be9e-4829-a183-629917778e4b">Clinical Studies (14)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b84a9df1-e320-4898-ae9e-0399382698ff">
                     <id root="32c41cf3-97db-018d-e063-6394a90ad851"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>In a study of healthy subjects, after topical ocular administration of 30 μL of atropine sulfate ophthalmic solution 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate. The median (range) time to maximum plasma concentration (Tmax) was 19 minutes (range 3 to 60 minutes), and the mean (±SD) peak plasma concentration (Cmax) of l-hyoscyamine was 288 ± 73 pg/mL. The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.</paragraph>
                        <paragraph>In a separate study of patients undergoing ocular surgery, after topical ocular administration of 40 μL of atropine sulfate ophthalmic solution, 1%, the mean (± SD) plasma Cmax of l-hyoscyamine was 860 ± 402 pg/mL, which was observed within 8 minutes following administration.</paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1fd70036-76bc-4b9b-bfbc-61c96f83b421">
               <id root="32c41cf3-97dc-018d-e063-6394a90ad851"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220303"/>
               <component>
                  <section ID="ID_db524f21-edab-408e-b34b-63bae47f50d5">
                     <id root="32c41cf3-97dd-018d-e063-6394a90ad851"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Atropine sulfate was negative in the
 
  <content styleCode="italics">Salmonella</content>/microsome mutagenicity test. Studies to evaluate carcinogenicity and impairment of fertility have not been conducted.

 </paragraph>
                     </text>
                     <effectiveTime value="20220303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ac7c1d64-be9e-4829-a183-629917778e4b">
               <id root="32c41cf3-97de-018d-e063-6394a90ad851"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Topical administration of Atropine Sulfate Ophthalmic Solution, USP 1% results in mydriasis and/or cycloplegia with efficacy demonstrated in both adults and children. The maximum effect for mydriasis is achieved in about 30–40 minutes after administration, with recovery after approximately 7–10 days. The maximum effect for cycloplegia is achieved within 60–180 minutes after administration, with recovery after approximately 7–12 days.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
            </section>
         </component>
         <component>
            <section ID="ID_5df66b8d-db29-4e3b-ad72-5105c88e84d3">
               <id root="32c41cf3-97df-018d-e063-6394a90ad851"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Atropine Sulfate Ophthalmic Solution, USP 1% is supplied as an aseptically prepared, sterile solution for topical ophthalmic use supplied as a 0.4 mL fill in a translucent, low-density polyethylene, single-dose vial. One (1) strip of 5 single-dose vials is packaged into a foil pouch.</paragraph>
                  <paragraph>NDC  82260-001-01  10 single-dose vials. 2 foil pouches each containing one strip of 5 single-dose vials.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling:</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F).</paragraph>
                  <paragraph>Store single-dose vials in the foil pouches. Opened vials cannot be resealed and should be discarded immediately after use.</paragraph>
               </text>
               <effectiveTime value="20220303"/>
            </section>
         </component>
         <component>
            <section ID="ID_fa5255b4-903c-436e-87be-2f55a17016e2">
               <id root="32c41cf3-97e0-018d-e063-6394a90ad851"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered">
                     <item>Advise patients that drops will sting upon instillation that they may experience blurry vision and sensitivity to light and should protect their eyes in bright illumination during dilation. These effects may last up to a couple weeks.</item>
                     <item>Advise patients to keep the single-dose vials in the foil pouches until ready to use. The solution from one single-dose vial is to be used immediately after opening to dose one or both eye(s) of a single patient. The single-dose vial, including any remaining contents, should be discarded immediately after administration
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ID_26236c0c-38ba-4aad-a7a5-f169321ecfd2">Dosage and Administration (2)</linkHtml>]
  
   </content>.
 
  </item>
                     <item>Advise patients not to touch the tip of the single-dose vial to their eye or to any surface, in order to avoid eye injury or contamination of the solution.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>  Bausch &amp; Lomb Americas Inc. 
  <br/>  Bridgewater, NJ 08807 USA

 </paragraph>
                  <paragraph>© 2022 Bausch &amp; Lomb Incorporated or its affiliates</paragraph>
                  <paragraph>9775600</paragraph>
               </text>
               <effectiveTime value="20220303"/>
            </section>
         </component>
         <component>
            <section ID="ID_0cb0825c-cdc3-4dcc-9c25-e6550580703e">
               <id root="32c41cf3-97e1-018d-e063-6394a90ad851"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content>82260-001-01 

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Atropine Sulfate</content>
                     <br/>
                     <content styleCode="bold">Ophthalmic</content>
                     <br/>
                     <content styleCode="bold">Solution, USP</content>
                     <br/>
                     <content styleCode="bold">1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL OPHTHALMIC USE</content>
                     <br/>
                     <content styleCode="bold">NOT FOR INJECTION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">EYE IMAGE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">10 x 0.4 mL</content>
                     <br/>
                     <content styleCode="bold">Single-Dose Vials</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BAUSCH + LOMB</content>
                  </paragraph>
                  <paragraph>9769201</paragraph>
                  <renderMultiMedia ID="id149112656" referencedObject="ID_774a189a-5884-49d1-b68f-01d52e188d65"/>
               </text>
               <effectiveTime value="20220303"/>
               <component>
                  <observationMedia ID="ID_774a189a-5884-49d1-b68f-01d52e188d65">
                     <text>AG CARTON</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>